MA-QUANTORI
20.7.2021 12:02:11 CEST | Business Wire | Press release
Quantori, a leading data science and digital transformation services company for the life sciences and healthcare sectors, today announced the appointment of Sean Murphy as Vice President of Client Services, effective immediately. Sean will oversee Quantori’s global network of IT professionals providing world-class software engineering and data analytics services to top biopharma and healthcare companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210720005589/en/
“Sean has a strong track record of leading cross-functional teams to deliver innovative digital IT solutions that support a seamless digital transformation experience,” said Richard Golob, CEO of Quantori. “As we enter our next phase of growth, we are thrilled to welcome Sean aboard to ensure delivery of cost-effective, high-quality data science and software engineering services.”
Sean has held various leadership positions at AstraZeneca and Thermo Fisher Scientific, where he focused primarily on R&D IT and Cloud and Digital Transformations. At AstraZeneca, Sean designed, developed, and led the Application Lifecycle Services organization, a world-class software engineering team that delivers quality products and services throughout AstraZeneca. He also was instrumental in establishing captive offshore development centers for AstraZeneca.
Most recently, Sean served as Vice President at General Electric, where he was the Technology Leader for the business and digital transformation of corporate systems. He focused predominately on the implementation of the enterprise SaaS solution Workday across all General Electric businesses.
Sean received his B.S. degree in Business Administration from the University of New Hampshire and his M.Sc. degree in Management with a specialization in Biopharmaceutical Leadership from Emmanuel College. He currently serves as a board member of the United Nations Association of Greater Boston and has served as a board member of the Society for Information Management of Boston and Newton Girls Soccer.
“I’m excited to join the highly impressive Quantori leadership team to help deliver nextgen data science and software solutions that provide immediate value for our clients,” according to Sean. “While at AstraZeneca, I had the pleasure of working with some of the professionals who are now Quantori’s leaders. They were the only service providers who truly understood the drug development process and the scientific problems we were trying to solve. I was so impressed with their performance and ability to deliver that I wanted to join the team!”
Quantori’s executive leadership boasts a rich history in the life sciences and healthcare IT industry. CEO Richard Golob, Chief Scientific Officer Yuriy Gankin, Ph.D., and Chief Technology Officer Vitaliy Aronov have successfully joined forces for more than two decades to deliver award-winning software engineering and data analytics services to top pharmaceutical companies and research organizations around the globe. They previously cofounded GGA Software Services, which was acquired by EPAM Systems in 2014. Golob built EPAM’s Life Sciences Business Unit into the fastest growing unit at the company.
“What we’ve experienced over the past year is that our clients require a versatile digital IT services provider that understands their needs for scalability and flexibility and has deep domain and data science knowledge, and Quantori checks all these boxes,” said Yuriy Gankin, Chief Scientific Officer at Quantori. “Sean’s background in helping organizations navigate the digital revolution will be invaluable in helping us fulfill our mission to empower our clients to achieve their strategic business goals.”
Quantori’s global headquarters are located in Cambridge, Massachusetts, with additional offices in London, U.K., St. Petersburg, Russia, and Tbilisi, Georgia. The company serves leading research institutions and biopharma organizations, including Bruker, The Jackson Laboratory, Perkin Elmer, and Takeda. Quantori’s team is currently more than 400 professionals, and the company is actively seeking qualified experts globally to keep pace with its rapid growth. For more information, please visit www.quantori.com or email info@quantori.com .
“The robust software engineering, scientific informatics and data science capabilities that Quantori offers have enabled us to achieve our IT strategy by harnessing the power of innovative digital technologies,” said Scott Thomas, Vice President of Information Technology for the LGC Genomics Division. “The COVID-19 pandemic has significantly increased demand for genomic analysis, and Quantori’s digital solutions have helped optimize our operations to meet the demand for these mission-critical applications.”
About Quantori
Quantori is transforming life sciences and healthcare with the power of digital IT. The company develops bespoke IT and data science solutions for accelerating research and drug discovery and improving healthcare delivery. Quantori combines data engineering and advanced analytics with scientific knowledge management and best-in-class software engineering to help life science and healthcare companies successfully achieve their digital transformations with greater speed and agility. Learn more at www.quantori.com and connect on social media @Twitter , @LinkedIn , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005589/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 01:00:00 CEST | Press release
-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP-Atebrioz expected to be available in the United States in October through Mirum Access Plus (MAP), with eligible patients paying as little as $0 per month-PROGRESS pediatric development program continues to evaluate zilurgisertib in children aged 2 to <12 years Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for pe
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 21:19:00 CEST | Press release
The offtake agreement connects Digital Reef’s 3.3 GW data centre pipeline with environmental assets from more than 30 million hectares of Amazon rainforest across South America, where Oreasoc Agriculture works directly on the ground alongside local communities to develop sustainable economies and safeguard their territories. Xange.com’s digital MRV technology monitors both the data centres and the rainforest. At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where D
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 15:00:00 CEST | Press release
Planned acquisition strengthens NetApp's position in the rapidly growing AI infrastructure market by bringing differentiated metadata innovation and parallel file architecture designed for AI NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata fr
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 14:57:00 CEST | Press release
The Group was recognised for the strength of its global institutional ecosystem and its contribution to financial markets innovation and community impact MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity
Croma-Pharma Introduces saypha® volume prime Lidocaine25.9.2026 14:04:00 CEST | Press release
New cross-linked hyaluronic acid filler replaces saypha® volume Lidocaine, offering physicians a more versatile solution for both midface volumization and nasolabial folds Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom